NanoRepro AG (NN6):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8078)
◆英語タイトル:NanoRepro AG (NN6) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8078
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:27
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
NanoRepro AG (NanoRepro) is a manufacturer of fast-diagnostics and nutritional food supplements for home and clinical use. The company offers wide range of rapid diagnostic tests products in the areas of family planning, disease detection (preventive healthcare), food intolerances, allergies and infectious diseases. Its products portfolio includes ovuquick, graviquick, glutencheck, cholesterincheck, fertiquick, vagiquick, menoquick, graviquick fruhtest, fobcheck, heli-c-check, alkoholtest, milkcheck, allergocheck, and eiercheck. The company works in partnership with companies and institutions including University of Marburg, Research Center for Medical Engineering and Biotechnology, Bad Langensalza, Germany. Dedicare AB, Hartmann USA, Inc., Farmaceutica Remedia SA, and others. The Company markets its products through a network of distributors worldwide. NanoRepro is headquartered in Marburg, Germany.

NanoRepro AG (NN6) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NanoRepro AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
NanoRepro AG, Medical Devices Deals, 2012 to YTD 2018 9
NanoRepro AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
NanoRepro AG, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
NanoRepro Acquires Alphabiol Brand from Alphablom 11
Equity Offering 12
Nanorepro Raises USD0.6 Million in Rights Offering of Shares 12
NanoRepro Raises USD1 Million in Rights Offering of Shares 13
NanoRepro to Raise Funds through Public Offering of Shares 14
NanoRepro Raises USD1.7 Million in Rights Offering of Shares 15
NanoRepro Raises USD1.1 Million in Rights Offering of Shares 16
NanoRepro AG – Key Competitors 17
NanoRepro AG – Key Employees 18
NanoRepro AG – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Financial Announcements 20
Apr 25, 2018: NanoRepro Increases Sales and Achieves Positive Operating Result (EBITDA) 20
Dec 05, 2017: NanoRepro With Higher Sales and Better Results 21
Aug 03, 2017: NanoRepro Increases Growth in the Second Quarter 22
Apr 25, 2017: NanoRepro: Sales Grow in the First Quarter 23
Apr 21, 2017: NanoRepro: Company Expects Revenue to Increase by at Least 30% in 2017 24
Jan 25, 2017: NanoRepro Announces Preliminary Figures for the 2016 Financial Year 25
Other Significant Developments 26
Apr 10, 2018: NanoRepro Reaches Its Annual Targets and Wants to Grow Strongly in 2018 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
NanoRepro AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NanoRepro AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NanoRepro AG, Deals By Therapy Area, 2012 to YTD 2018 8
NanoRepro AG, Medical Devices Deals, 2012 to YTD 2018 9
NanoRepro AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
NanoRepro Acquires Alphabiol Brand from Alphablom 11
Nanorepro Raises USD0.6 Million in Rights Offering of Shares 12
NanoRepro Raises USD1 Million in Rights Offering of Shares 13
NanoRepro to Raise Funds through Public Offering of Shares 14
NanoRepro Raises USD1.7 Million in Rights Offering of Shares 15
NanoRepro Raises USD1.1 Million in Rights Offering of Shares 16
NanoRepro AG, Key Competitors 17
NanoRepro AG, Key Employees 18

List of Figures
NanoRepro AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NanoRepro AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
NanoRepro AG, Medical Devices Deals, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ NanoRepro AG (NN6):製薬・医療:M&Aディール及び事業提携情報(NanoRepro AG (NN6) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆